MyMD Pharmaceuticals Announces 1-For-30 Reverse Stock Split To Maintain Nasdaq Listing
Portfolio Pulse from Benzinga Newsdesk
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) announced a 1-for-30 reverse stock split effective February 14, 2024, to maintain its Nasdaq listing. The split-adjusted trading will start on February 15, 2024. This move will convert every 30 shares into one and reduce the authorized shares from 500,000,000 to 16,666,666. The action aims to comply with Nasdaq's listing requirements and does not require physical stock certificate exchanges for shareholders.

February 13, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
MyMD Pharmaceuticals announces a 1-for-30 reverse stock split to maintain its Nasdaq listing, effective February 14, 2024, with split-adjusted trading starting February 15, 2024.
Reverse stock splits are often used by companies to maintain listing requirements by increasing the stock price, although they do not inherently change the company's market value. For MYMD, this move is likely aimed at meeting Nasdaq's minimum bid price requirement. The short-term impact on the stock price could be neutral to slightly positive as it reflects the company's efforts to comply with Nasdaq standards. However, investor perception of reverse splits can vary, and the long-term impact depends on the company's future performance and investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100